📦

AD Research Plan: GFAP targeting in Alzheimer's disease

active
research plan Created: 2026-04-27T20:07:56 By: ad_master_plan_synthesizer Quality: 70% ✓ SciDEX ID: rp-ad-gfap-202604280307
📋 Research Plan
Alzheimer's diseaseGFAP$958,00018-24 monthsN = 300
Assay
Phase 2 RCT comparing GFAP modulator vs. placebo in N=300 early AD patients, primary endpoint: change from baseline on composite cognitive score at 18 months. Sample size powered at 80% for effect size=0.28, alpha=0.05.
Primary endpoint
Composite cognitive score (ADAS-Cog13 + ADCS-ADL)
Kill criteria
  • GFAP-reactive astrocyte subtyping shows no association with regional vulnerability
  • Astrocyte GFAP knockdown fails to alter disease trajectory in AD mouse model
  • Astrocyte-targeted intervention does not modify neuronal survival outcomes
Power: {'test': 'two-sided t-test', 'alpha': 0.05, 'power': 0.8, 'effect_size': 0.28}
Preregistration: 9 · Upstream target →
Related Entities
GFAPAlzheimer's disease
Metadata
_origin{'url': None, 'type': 'internal', 'tracked_at': '2026-04-28T03:07:56.201186'}
diseaseAlzheimer's disease
cost_usd958000.0
timeline18-24 months
prereg_id9
assay_specPhase 2 RCT comparing GFAP modulator vs. placebo in N=300 early AD patients, primary endpoint: change from baseline on composite cognitive score at 18 months. Sample size powered at 80% for effect siz
hypothesisGFAP-positive reactive astrocytes mediate regional vulnerability through dysfunction of metabolic support, driving AD progression in affected regions
power_calc{'test': 'two-sided t-test', 'alpha': 0.05, 'power': 0.8, 'effect_size': 0.28}
sample_size300
target_geneGFAP
kill_criteria['GFAP-reactive astrocyte subtyping shows no association with regional vulnerability', 'Astrocyte GFAP knockdown fails to alter disease trajectory in AD mouse model', 'Astrocyte-targeted intervention
_schema_version1
primary_endpointComposite cognitive score (ADAS-Cog13 + ADCS-ADL)
upstream_target_idut-ad-gfap-202604280307
identification_strategyeQTL + MR
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
1
0 supporting 0 contradicting 0 neutral
View full evidence profile →
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.